Association between gene mutations and certain blood cell indices in patients diagnosed with myelodysplastic neoplasms

Nguyen,Quang Hao; Vu,Minh Phuong; Tran,Tuan Anh; Duong,Quoc Chinh; Vu,Duc Binh; Nguyen,Ha Thanh; Bach,Quoc Khanh

doi:10.3892/wasj.2024.238

Association between gene mutations and certain blood cell indices in patients diagnosed with myelodysplastic neoplasms

Authors:
- Quang Hao Nguyen
- Minh Phuong Vu
- Tuan Anh Tran
- Quoc Chinh Duong
- Duc Binh Vu
- Ha Thanh Nguyen
- Quoc Khanh Bach
View Affiliations

Affiliations: Clinical Hematology Department, Thai Nguyen National Hospital, Thai Nguyen 24124, Vietnam, Department of Hematology, Hanoi Medical University, Hanoi 11521, Vietnam, Department of Molecular Cytogenetics, National Institute of Hematology and Blood Transfusion, Hanoi 11312, Vietnam, Department of General Hematology, National Institute of Hematology and Blood Transfusion, Hanoi 11312, Vietnam, Department of Chemotherapy, National Institute of Hematology and Blood Transfusion, Hanoi 11312, Vietnam
Published online on: March 22, 2024 https://doi.org/10.3892/wasj.2024.238
Article Number: 23
Copyright : © Nguyen et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gene mutations play a crucial role in the pathogenesis of myelodysplastic neoplasms (MDS). The present study aimed to assess the association between some gene mutations and certain blood cell indices in patients diagnosed with MDS. The present study was a retrospective cross‑sectional study. Patients newly diagnosed with MDS, who underwent next‑generation sequencing, and which revealed 51 gene mutations, were enrolled in the present study. The peripheral blood cell indices were recorded before commencing treatment. There were 18 mutations to be found. The ASXL1 mutation was the most frequently encountered, followed by the RUNX1, TET2, SF3B1 and TP53 mutations. Patients with the U2AF1 mutation had a lower hemoglobin level, those with BCOR or SRSF2 mutations had a higher percentage of peripheral blood blasts, and those with the SF3B1 mutation had a higher platelet count compared to the group without this mutation. Receiver operating characteristic analysis was performed to determine the optimal cut‑off value for hemoglobin level, platelet count and the percentage of peripheral blood blasts. The optimal cut‑off value for the hemoglobin level to separate the presence of U2AF1 mutation was 56.5. The optimal cut‑off value for the percentage of peripheral blood blasts to separate the presence of BCOR and SRSF2 mutations was 7.5 and 5.5, respectively. The optimal cut‑off value for the platelet count to separate the presence of the SF3B1 mutation was 228.5. The results also revealed that a hemoglobin level <56.5 g/l, platelet count >228.5 G/l, and a percentage of peripheral blood blasts >7.5 and >5.5% was associated with U2AF1, SF3B1, BCOR and SRSF2 mutations. On the whole, the present study demonstrates that there is an association between gene mutations and blood cell indices in patients diagnosed with MDS. The U2AF1 mutation is associated with severe anemia, and BCOR and SRSF2 mutations are associated with MDS with increased blast numbers. However, the SF3B1 mutation is related to a good platelet count.

View Figures

View References

1	Marques FK and Sabino AP: Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment. Biomed Pharmacother. 156(113905)2022.PubMed/NCBI View Article : Google Scholar
2	Ogawa S: Genetics of MDS. Blood. 133:1049–1059. 2019.PubMed/NCBI View Article : Google Scholar
3	Nakajima H: Molecular pathogenesis and treatment of myelodysplastic syndromes. Intern Med. 60:15–23. 2021.PubMed/NCBI View Article : Google Scholar
4	Shallis RM, Ahmad R and Zeidan AM: The genetic and molecular pathogenesis of myelodysplastic syndromes. Eur J Haematol. 101:260–271. 2018.PubMed/NCBI View Article : Google Scholar
5	Haferlach T: The molecular pathology of myelodysplastic syndrome. Pathobiology. 86:24–29. 2019.PubMed/NCBI View Article : Google Scholar
6	Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers TM, Wells DA, et al: Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 8:73483–73500. 2017.PubMed/NCBI View Article : Google Scholar
7	Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405. 2016.PubMed/NCBI View Article : Google Scholar
8	Garcia-Manero G: Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 98:1307–1325. 2023.PubMed/NCBI View Article : Google Scholar
9	Bejar R: Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica. 99:956–964. 2014.PubMed/NCBI View Article : Google Scholar
10	Martín I, Such E, Navarro B, Villamón E, Vicente A, Mora E, Pedrola L, Ibáñez M, López-Pavía M, Tormo M, et al: Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts. Blood Cancer J. 7(630)2017.PubMed/NCBI View Article : Google Scholar
11	Maurya N, Mohanty P, Dhangar S, Panchal P, Jijina F, Mathan SLP, Shanmukhaiah C, Madkaikar M and Vundinti BR: Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes. Sci Rep. 12(5925)2022.PubMed/NCBI View Article : Google Scholar
12	Ma J, Gu Y, Wei Y, Wang X, Wang P, Song C and Ge Z: Evaluation of new IPSS-Molecular model and comparison of different prognostic systems in patients with myelodysplastic syndrome. Blood Sci. 5:187–195. 2023.PubMed/NCBI View Article : Google Scholar
13	Lee WH, Tsai MT, Tsai CH, Tien FM, Lo MY, Tseng MH, Kuo YY, Liu MC, Yang YT, Chen JC, et al: Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification. Blood Cancer J. 13(120)2023.PubMed/NCBI View Article : Google Scholar
14	Gu S, Xia J, Tian Y, Zi J and Ge Z: A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS. BMC Cancer. 21(134)2021.PubMed/NCBI View Article : Google Scholar
15	Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, et al: The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 36:1703–1719. 2022.PubMed/NCBI View Article : Google Scholar
16	Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, Devlin SM, Creignou M, Pinel P, Monnier L, et al: Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 1(EVIDoa2200008)2022.PubMed/NCBI View Article : Google Scholar
17	von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC and Vandenbroucke JP: STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol. 61:344–349. 2008.PubMed/NCBI View Article : Google Scholar
18	Cook MR, Karp JE and Lai C: The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication? EJHaem. 3:301–313. 2021.PubMed/NCBI View Article : Google Scholar
19	Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D and Ebert BL: Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 364:2496–2506. 2011.PubMed/NCBI View Article : Google Scholar
20	Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T, et al: Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 28:241–247. 2014.PubMed/NCBI View Article : Google Scholar
21	Zhao P, Qin J, Liu W, Quan R, Xiao H, Liu C, Li L, Lv Y, Zhu Q, Wang H, et al: Genetic alterations in 47 patients with a novel myelodysplastic syndrome diagnosis at a single center. Oncol Lett. 18:5077–5084. 2019.PubMed/NCBI View Article : Google Scholar
22	Yu J, Li Y, Li T, Li Y, Xing H, Sun H, Sun L, Wan D, Liu Y, Xie X and Jiang Z: Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia. Exp Hematol Oncol. 9(2)2020.PubMed/NCBI View Article : Google Scholar
23	Liu M, Wang F, Zhang Y, Chen X, Cao P, Nie D, Fang J, Wang M, Liu M and Liu H: Gene mutation spectrum of patients with myelodysplastic syndrome and progression to acute myeloid leukemia. Int J Hematol Oncol. 10(IJH34)2021.PubMed/NCBI View Article : Google Scholar
24	Saygin C and Godley LA: Genetics of myelodysplastic syndromes. Cancers (Basel). 13(3380)2021.PubMed/NCBI View Article : Google Scholar
25	Kennedy JA and Ebert BL: Clinical implications of genetic mutations in myelodysplastic syndrome. J Clin Oncol. 35:968–974. 2017.PubMed/NCBI View Article : Google Scholar
26	Polprasert C, Kongkiatkamon S, Niparuck P, Rattanathammethee T, Wudhikarn K, Chuncharunee S, Kobbuaklee S, Suksusut A, Lanamtieng T, Lawasut P, et al: Genetic mutations associated with blood count abnormalities in myeloid neoplasms. Hematology. 27:765–771. 2022.PubMed/NCBI View Article : Google Scholar
27	Stockton SS, Malhotra V, Lu X, Thangavelu M, Albitar M and Cogle CR: Gene mutations in MDS associating with peripheral blood count abnormalities. Blood. 126(1685)2015.